Brand Name | Status | Last Update |
---|---|---|
enbrel | Biologic Licensing Application | 2024-09-12 |
Expiration | Code | ||
---|---|---|---|
etanercept, Enbrel, Immunex Corporation | |||
2106-05-27 | Orphan excl. | ||
etanercept, Enbrel Mini, Immunex Corporation | |||
2106-05-27 | Orphan excl. |
Code | Description |
---|---|
J1438 | Injection, etanercept, 25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Arthritis | D001168 | HP_0001369 | M05-M14 | 7 | 14 | 54 | 72 | 75 | 218 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 7 | 12 | 43 | 63 | 68 | 191 |
Psoriasis | D011565 | EFO_0000676 | L40 | 4 | 6 | 37 | 31 | 37 | 112 |
Spondylitis | D013166 | — | M46.9 | — | 6 | 9 | 25 | 29 | 68 |
Spondylarthritis | D025241 | — | — | — | 6 | 9 | 23 | 24 | 61 |
Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 4 | 9 | 17 | 23 | 52 |
Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | — | 7 | 9 | 16 | 32 |
Juvenile arthritis | D001171 | EFO_1002007 | M08 | 1 | 3 | 10 | 2 | 5 | 19 |
Necrosis | D009336 | — | — | 1 | 7 | 2 | 2 | 5 | 14 |
Inflammation | D007249 | MP_0001845 | — | — | 2 | 2 | 1 | 4 | 9 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Syndrome | D013577 | — | — | 2 | 9 | 4 | — | 6 | 17 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 8 | 11 | 3 | — | — | 15 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 5 | 7 | 2 | — | — | 9 |
Graft vs host disease | D006086 | — | D89.81 | — | 5 | 2 | — | — | 7 |
Neoplasms | D009369 | — | C80 | 3 | 1 | 1 | — | — | 4 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | 1 | — | 3 | 4 |
Uveitis | D014605 | HP_0000554 | H20.9 | — | 1 | 1 | — | 1 | 3 |
Pneumonia | D011014 | EFO_0003106 | — | 1 | 2 | 1 | — | — | 3 |
Rheumatic diseases | D012216 | — | M79.0 | — | — | 1 | — | 1 | 2 |
Stevens-johnson syndrome | D013262 | EFO_0004276 | L51.1 | — | — | 1 | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 11 | 2 | — | — | — | 13 |
Leukemia | D007938 | — | C95 | 2 | 6 | — | — | — | 6 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | 4 | 1 | — | — | 1 | 6 |
Myelodysplastic syndromes | D009190 | — | D46 | 2 | 5 | — | — | — | 5 |
Preleukemia | D011289 | — | — | 2 | 5 | — | — | — | 5 |
Lymphoma | D008223 | — | C85.9 | 2 | 2 | — | — | — | 3 |
Hidradenitis suppurativa | D017497 | — | L73.2 | — | 2 | — | — | 1 | 3 |
Hidradenitis | D016575 | — | — | — | 2 | — | — | 1 | 3 |
Asthma | D001249 | EFO_0000270 | J45 | — | 2 | — | — | 1 | 3 |
Myeloproliferative disorders | D009196 | — | D47.1 | 1 | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | 2 | 3 |
Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 1 | 2 |
Metabolic bone diseases | D001851 | HP_0000938 | — | 1 | — | — | — | — | 1 |
Osteoporosis | D010024 | HP_0000939 | M81.0 | 1 | — | — | — | — | 1 |
Postmenopause | D017698 | — | — | 1 | — | — | — | — | 1 |
Persian gulf syndrome | D018923 | EFO_0007430 | — | 1 | — | — | — | — | 1 |
Occupational diseases | D009784 | — | — | 1 | — | — | — | — | 1 |
Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Hemorrhage | D006470 | MP_0001914 | R58 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Depression | D003863 | — | F33.9 | — | — | — | — | 2 | 2 |
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 2 | 2 |
Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | — | — | 2 | 2 |
Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | — | 2 | 2 |
Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 2 | 2 |
Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | — | 2 | 2 |
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 2 | 2 |
Skin diseases | D012871 | — | L00-L99 | — | — | — | — | 2 | 2 |
Papulosquamous skin diseases | D017444 | — | L40-L45 | — | — | — | — | 2 | 2 |
Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
Drug common name | Etanercept |
INN | etanercept |
Description | Etanercept, sold under the brand name Enbrel among others, is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. TNF-alpha is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha.
|
Classification | Protein |
Drug class | receptor molecules or membrane ligands, natural, modified or modified: tumor necrosis factor receptors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201572 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00005 |
UNII ID | OP401G7OJC (ChemIDplus, GSRS) |